Biofrontera AG (BFRA) Stock: Do Analysts Think You Should Sell?

Wednesday, February 09, 2022 09:51 AM | InvestorsObserver Analysts

Mentioned in this article

Biofrontera AG (BFRA) Stock: Do Analysts Think You Should Sell?

Wall Street is positive on Biofrontera AG (BFRA). On average, analysts give Biofrontera AG a Strong Buy rating. The average price target is $8, which means analysts expect the stock to rise by 127.27% over the next twelve months. That average ranking earns Biofrontera AG an Analyst Rating of 73, which is better than 73% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating BFRA a Strong Buy today. Find out what this means to you and get the rest of the rankings on BFRA!

See Full BFRA Report

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With Biofrontera AG Stock Today?

Biofrontera AG (BFRA) stock is trading at $3.52 as of 9:46 AM on Wednesday, Feb 9, an increase of $0.38, or 12.06% from the previous closing price of $3.14. The stock has traded between $3.31 and $3.68 so far today. Volume today is high. So far 77,771 shares have traded compared to average volume of 24,782 shares. Click Here to get the full Stock Report for Biofrontera AG stock.